U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H22F3N
Molecular Weight 357.4128
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CINACALCET

SMILES

C[C@]([H])(c1cccc2ccccc21)NCCCc3cccc(c3)C(F)(F)F

InChI

InChIKey=VDHAWDNDOKGFTD-MRXNPFEDSA-N
InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1

HIDE SMILES / InChI

Molecular Formula C22H22F3N
Molecular Weight 357.4128
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Cinacalcet is a positive allosteric modulator of calcium sensing receptor. The drug is approved by FDA (Sensipar trade name) and used for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis; hypercalcemia in adult patients with parathyroid carcinoma; hypercalcemia in adult patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SENSIPAR

Approved Use

Sensipar is a calcium-sensing receptor agonist indicated for: Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease on dialysis; Hypercalcemia in adult patients with Parathyroid Carcinoma; Hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy.

Launch Date

1.07870401E12
Primary
SENSIPAR

Approved Use

Sensipar is a calcium-sensing receptor agonist indicated for: Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease on dialysis; Hypercalcemia in adult patients with Parathyroid Carcinoma; Hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy.

Launch Date

1.07853119E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
29.9 ng/mL
90 mg single, oral
dose: 90 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CINACALCET blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: HIGH-FAT
26.6 ng/mL
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CINACALCET plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
20.6 ng/mL
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CINACALCET plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
323 ng × h/mL
90 mg single, oral
dose: 90 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CINACALCET blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: HIGH-FAT
296 ng × h/mL
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CINACALCET plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
346 ng × h/mL
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CINACALCET plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12.4 h
90 mg single, oral
dose: 90 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CINACALCET blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: HIGH-FAT
30.4 h
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CINACALCET plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
33.6 h
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CINACALCET plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg single, oral
Highest studied dose
Dose: 100 mg
Route: oral
Route: single
Dose: 100 mg
Sources:
healthy, 20 - 35 years
n = 6
Health Status: healthy
Age Group: 20 - 35 years
Sex: M
Population Size: 6
Sources:
Other AEs: Nasal congestion, Diarrhea...
Other AEs:
Nasal congestion (1 patient)
Diarrhea (1 patient)
Dyspepsia (3 patients)
Peripheral sensory neuropathy (1 patient)
Vomiting (1 patient)
Sources:
300 mg 1 times / day multiple, oral
Highest studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 49 years (range: 31-71 years)
n = 7
Health Status: unhealthy
Age Group: 49 years (range: 31-71 years)
Sex: M+F
Population Size: 7
Sources:
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Other AEs: Anaemia, Coagulopathy...
Other AEs:
Anaemia (serious, 42 patients)
Coagulopathy (serious, 2 patients)
Anaemia haemolytic (serious, 1 patient)
Haemorrhagic anaemia (serious, 5 patients)
Haemorrhagic disorder (serious, 1 patient)
Leukocytosis (serious, 4 patients)
Leukopenia (serious, 2 patients)
Neutropenia (serious, 2 patients)
Acute myocardial infarction (serious, 47 patients)
Angina unstable (serious, 52 patients)
Aortic valve stenosis (serious, 7 patients)
Atrial flutter (serious, 12 patients)
Atrial tachycardia (serious, 1 patient)
Atrioventricular block (serious, 5 patients)
Bradycardia (serious, 12 patients)
Block bundle branch (serious, 1 patient)
Cardiac arrest (serious, 60 patients)
Cardiac failure acute (serious, 6 patients)
Cardio-respiratory arrest (serious, 27 patients)
Cardiogenic shock (serious, 12 patients)
Cardiovascular disorder (serious, 1 patient)
Coronary artery disease (serious, 28 patients)
Coronary artery insufficiency (serious, 1 patient)
Coronary artery stenosis (serious, 5 patients)
Dilatation ventricular (serious, 1 patient)
Left ventricular dysfunction (serious, 2 patients)
Mitral valve calcification (serious, 1 patient)
Mitral valve disease (serious, 2 patients)
Myocardial infarction (serious, 109 patients)
Myocardial ischaemia (serious, 11 patient)
Palpitations (serious, 6 patients)
Pericardial effusion (serious, 8 patients)
Pericarditis (serious, 3 patients)
Right ventricular failure (serious, 2 patients)
Sinus tachycardia (serious, 2 patients)
Supraventricular extrasystoles (serious, 1 patient)
Ventricular tachyarrhythmia (serious, 1 patient)
Ventricular tachycardia (serious, 12 patients)
Adenomatous polyposis coli (serious, 1 patient)
Congenital cystic kidney disease (serious, 6 patients)
Gastrointestinal arteriovenous malformation (serious, 2 patients)
Left ventricle outflow tract obstruction (serious, 1 patient)
Meniere's disease (serious, 1 patient)
Vertigo (serious, 4 patients)
Vertigo positional (serious, 1 patient)
Disorder vestibular (serious, 1 patient)
Adrenal insufficiency (serious, 1 patient)
Parathyroid gland enlargement (serious, 2 patients)
Thyroid cyst (serious, 1 patient)
Thyroiditis (serious, 1 patient)
Age-related macular degeneration (serious, 1 patient)
Cataract (serious, 8 patients)
Cataract cortical (serious, 1 patient)
Conjunctivitis (serious, 2 patients)
Diabetic retinopathy (serious, 1 patient)
Exophthalmos (serious, 1 patient)
Eye haemorrhage (serious, 3 patients)
Atrophy optic (serious, 1 patient)
Retinal detachment (serious, 3 patients)
Retinal vein thrombosis (serious, 1 patient)
Hypertensive retinopathy (serious, 1 patient)
Visual impairment (serious, 1 patient)
Vitreous haemorrhage (serious, 2 patients)
Abdominal distension (serious, 1 patient)
Abdominal hernia obstructive (serious, 1 patient)
Abdominal pain upper (serious, 5 patients)
Abdominal rigidity (serious, 1 patient)
Abdominal strangulated hernia (serious, 2 patients)
Barrett's oesophagus (serious, 1 patient)
Colitis ischaemic (serious, 9 patients)
Constipation (serious, 8 patients)
Diabetic gastroparesis (serious, 2 patients)
Diarrhoea (serious, 32 patients)
Dieulafoy's vascular malformation (serious, 1 patient)
Diverticular perforation (serious, 2 patients)
Diverticulum (serious, 1 patient)
Duodenal ulcer (serious, 7 patients)
Dyspepsia (serious, 3 patients)
Dysphagia (serious, 3 patients)
Enteritis (serious, 5 patients)
Erosive oesophagitis (serious, 1 patient)
Faecaloma (serious, 3 patients)
Gastric hypermotility (serious, 1 patient)
Gastric ulcer (serious, 12 patients)
Gastric ulcer haemorrhage (serious, 2 patients)
Gastritis haemorrhagic (serious, 1 patient)
Gastroduodenitis (serious, 1 patient)
Gastrointestinal angiodysplasia (serious, 2 patients)
Gastrointestinal haemorrhage (serious, 54 patients)
Gastrointestinal inflammation (serious, 2 patients)
Gastrointestinal ulcer haemorrhage (serious, 1 patient)
Gastrooesophageal reflux disease (serious, 4 patients)
Haematemesis (serious, 5 patients)
Haemorrhagic erosive gastritis (serious, 1 patient)
Haemorrhoids (serious, 5 patients)
Hernial eventration (serious, 1 patient)
Hiatus hernia (serious, 2 patients)
Ileus (serious, 6 patients)
Impaired gastric emptying (serious, 6 patients)
Intestinal haemorrhage (serious, 2 patients)
Intestinal ischaemia (serious, 9 patients)
Intestinal mass (serious, 1 patient)
Intestinal obstruction (serious, 5 patients)
Intestinal perforation (serious, 1 patient)
Intestinal ulcer (serious, 1 patient)
Irritable bowel syndrome (serious, 1 patient)
Ischaemic gastritis (serious, 1 patient)
Intestinal large ulcer (serious, 1 patient)
Lumbar hernia (serious, 1 patient)
Mechanical ileus (serious, 1 patient)
Melaena (serious, 3 patients)
Mesenteric artery stenosis (serious, 2 patients)
Nausea (serious, 20 patients)
Necrotising colitis (serious, 1 patient)
Achalasia oesophageal (serious, 1 patient)
Oesophageal food impaction (serious, 1 patient)
Oesophageal perforation (serious, 1 patient)
Oesophagitis (serious, 6 patients)
Oesophagitis haemorrhagic (serious, 1 patient)
Chronic pancreatitis (serious, 2 patients)
Peptic ulcer haemorrhage (serious, 1 patient)
Haemorrhage retroperitoneal (serious, 1 patient)
Short-bowel syndrome (serious, 1 patient)
Small intestinal obstruction (serious, 5 patients)
Stomach mass (serious, 1 patient)
Stress ulcer (serious, 1 patient)
Subileus (serious, 1 patient)
Tooth loss (serious, 1 patient)
Tooth socket haemorrhage (serious, 1 patient)
Upper gastrointestinal haemorrhage (serious, 11 patient)
Vomiting (serious, 33 patients)
Catheter site haematoma (serious, 3 patients)
Catheter site pain (serious, 1 patient)
Catheter site swelling (serious, 1 patient)
Chest discomfort (serious, 4 patients)
Chills (serious, 4 patients)
Device dislocation (serious, 2 patients)
Device occlusion (serious, 2 patients)
Drug intolerance (serious, 1 patient)
Drug withdrawal syndrome (serious, 1 patient)
Fat necrosis (serious, 1 patient)
Hernia (serious, 1 patient)
Hernia pain (serious, 1 patient)
Hyperthermia (serious, 2 patients)
Implant site haematoma (serious, 1 patient)
Influenza like illness (serious, 1 patient)
Localised oedema (serious, 1 patient)
Multi-organ failure (serious, 8 patients)
Necrosis (serious, 1 patient)
Non-cardiac chest pain (serious, 27 patients)
Organ failure (serious, 1 patient)
Pelvic mass (serious, 1 patient)
Precancerous mucosal lesion (serious, 1 patient)
Pyrexia (serious, 42 patients)
Spinal pain (serious, 2 patients)
Systemic inflammatory response syndrome (serious, 1 patient)
Bile duct stone (serious, 3 patients)
Cholangitis (serious, 3 patients)
Cholangitis acute (serious, 1 patient)
Cholecystitis acute (serious, 7 patients)
Cholecystitis chronic (serious, 1 patient)
Cholelithiasis (serious, 16 patients)
Cholestasis (serious, 2 patients)
Gallbladder polyp (serious, 2 patients)
Hepatic function abnormal (serious, 1 patient)
Hepatic lesion (serious, 1 patient)
Amyloidosis (serious, 1 patient)
Kidney transplant rejection (serious, 6 patients)
Abdominal abscess (serious, 2 patients)
Abdominal wall abscess (serious, 4 patients)
Abscess (serious, 3 patients)
Abscess limb (serious, 9 patients)
Abscess neck (serious, 1 patient)
Abscess of eyelid (serious, 1 patient)
Abscess oral (serious, 1 patient)
Acute sinusitis (serious, 1 patient)
Appendicitis (serious, 6 patients)
Appendicitis perforated (serious, 1 patient)
Arteriosclerotic gangrene (serious, 1 patient)
Arteriovenous graft site infection (serious, 25 patients)
Arthritis bacterial (serious, 4 patients)
Arthritis infective (serious, 2 patients)
Bacteraemia (serious, 27 patients)
Bacterial infection (serious, 1 patient)
Biliary tract infection (serious, 1 patient)
Bronchitis (serious, 26 patients)
Catheter site cellulitis (serious, 2 patients)
Cellulitis orbital (serious, 1 patient)
Clostridial infection (serious, 3 patients)
Clostridium colitis (serious, 1 patient)
Clostridium difficile colitis (serious, 9 patients)
Dengue fever (serious, 2 patients)
Device related infection (serious, 29 patients)
Diverticulitis (serious, 9 patients)
Endocarditis (serious, 13 patients)
Enteritis infectious (serious, 2 patients)
Enterobacter bacteraemia (serious, 2 patients)
Enterobacter pneumonia (serious, 1 patient)
Enterobacter sepsis (serious, 3 patients)
Enterococcal bacteraemia (serious, 3 patients)
Enterococcal infection (serious, 1 patient)
Enterocolitis infectious (serious, 2 patients)
Escherichia bacteraemia (serious, 1 patient)
Eye infection (serious, 2 patients)
Fungal oesophagitis (serious, 1 patient)
Gas gangrene (serious, 1 patient)
Gastroenteritis (serious, 24 patients)
Gastroenteritis viral (serious, 8 patients)
Giardiasis (serious, 1 patient)
H1N1 influenza (serious, 3 patients)
Haematoma infection (serious, 2 patients)
Haemophilus infection (serious, 2 patients)
Helicobacter infection (serious, 1 patient)
Hepatitis C (serious, 2 patients)
Herpes zoster (serious, 4 patients)
Implant site infection (serious, 1 patient)
Infected fistula (serious, 3 patients)
Infectious peritonitis (serious, 1 patient)
Infective aneurysm (serious, 1 patient)
Infective tenosynovitis (serious, 1 patient)
Influenza (serious, 4 patients)
Joint abscess (serious, 1 patient)
Klebsiella bacteraemia (serious, 1 patient)
Lower respiratory tract infection (serious, 11 patient)
Lower respiratory tract infection bacterial (serious, 1 patient)
Bacterial meningitis (serious, 1 patient)
Cryptococcal meningitis (serious, 1 patient)
Meningitis viral (serious, 1 patient)
Nasal abscess (serious, 1 patient)
Orchitis (serious, 1 patient)
Periorbital cellulitis (serious, 1 patient)
Perirectal abscess (serious, 2 patients)
Peritoneal abscess (serious, 1 patient)
Peritonitis (serious, 9 patients)
Abscess peritonsillar (serious, 1 patient)
Pilonidal cyst (serious, 1 patient)
Pneumonia escherichia (serious, 1 patient)
Pneumonia fungal (serious, 1 patient)
Pneumonia primary atypical (serious, 2 patients)
Pneumonia viral (serious, 2 patients)
Post procedural infection (serious, 1 patient)
Post procedural pneumonia (serious, 1 patient)
Postoperative abscess (serious, 3 patients)
Pseudomonas infection (serious, 1 patient)
Pulmonary tuberculosis (serious, 1 patient)
Pyelocystitis (serious, 1 patient)
Pyelonephritis (serious, 9 patients)
Pyelonephritis acute (serious, 2 patients)
Rectal abscess (serious, 1 patient)
Renal cyst infection (serious, 2 patients)
Respiratory tract infection bacterial (serious, 1 patient)
Respiratory tract infection viral (serious, 1 patient)
Scrotal abscess (serious, 1 patient)
Sepsis (serious, 123 patients)
Serratia bacteraemia (serious, 1 patient)
Staphylococcal bacteraemia (serious, 9 patients)
Infection staphylococcal (serious, 14 patients)
Staphylococcal osteomyelitis (serious, 2 patients)
Staphylococcal sepsis (serious, 12 patients)
Streptococcal sepsis (serious, 1 patient)
Subcutaneous abscess (serious, 6 patients)
Testicular abscess (serious, 1 patient)
Tooth abscess (serious, 1 patient)
Tooth infection (serious, 1 patient)
Upper respiratory tract infection (serious, 7 patients)
Vestibular neuronitis (serious, 1 patient)
Viral infection (serious, 5 patients)
Viral pharyngitis (serious, 1 patient)
Wound infection bacterial (serious, 1 patient)
Wound infection staphylococcal (serious, 2 patients)
Zygomycosis (serious, 1 patient)
Acetabulum fracture (serious, 2 patients)
Animal bite (serious, 1 patient)
Ankle fracture (serious, 9 patients)
Arteriovenous fistula occlusion (serious, 13 patients)
Arteriovenous fistula site haematoma (serious, 3 patients)
Arteriovenous fistula thrombosis (serious, 49 patients)
Arteriovenous graft aneurysm (serious, 2 patients)
Arteriovenous graft site haemorrhage (serious, 9 patients)
Brain herniation (serious, 1 patient)
Complications of transplanted kidney (serious, 3 patients)
Contusion (serious, 4 patients)
Cystitis radiation (serious, 1 patient)
Eye operation complication (serious, 1 patient)
Face injury (serious, 1 patient)
Forearm fracture (serious, 3 patients)
Foreign body (serious, 1 patient)
Fracture (serious, 3 patients)
Fractured coccyx (serious, 1 patient)
Graft complication (serious, 1 patient)
Graft haemorrhage (serious, 1 patient)
Graft thrombosis (serious, 7 patients)
Haemodialysis-induced symptom (serious, 4 patients)
In-stent coronary artery restenosis (serious, 2 patients)
Joint dislocation (serious, 5 patients)
Kidney rupture (serious, 1 patient)
Overdose (serious, 6 patients)
Pelvic fracture (serious, 3 patients)
Pneumothorax traumatic (serious, 1 patient)
Post procedural haemorrhage (serious, 5 patients)
Postoperative adhesion (serious, 1 patient)
Postoperative ileus (serious, 1 patient)
Postoperative thoracic procedure complication (serious, 1 patient)
Postoperative wound complication (serious, 2 patients)
Procedural complication (serious, 1 patient)
Procedural hypotension (serious, 10 patients)
Shunt aneurysm (serious, 1 patient)
Shunt occlusion (serious, 10 patients)
Shunt stenosis (serious, 6 patients)
Shunt thrombosis (serious, 8 patients)
Spinal column injury (serious, 1 patient)
Splenic rupture (serious, 1 patient)
Subdural haematoma (serious, 8 patients)
Suture rupture (serious, 1 patient)
Transplant failure (serious, 3 patients)
Vascular access complication (serious, 15 patients)
Vascular graft complication (serious, 13 patients)
Vascular graft occlusion (serious, 8 patients)
Vascular pseudoaneurysm (serious, 8 patients)
Wound dehiscence (serious, 4 patients)
Blood calcium decreased (serious, 1 patient)
Blood potassium increased (serious, 4 patients)
Blood pressure increased (serious, 2 patients)
C-reactive protein increased (serious, 2 patients)
Cardioactive drug level increased (serious, 1 patient)
Clostridium test positive (serious, 1 patient)
Electrocardiogram ST segment abnormal (serious, 1 patient)
Electrocardiogram ST-T segment abnormal (serious, 1 patient)
Electrocardiogram abnormal (serious, 2 patients)
Electrocardiogram change (serious, 3 patients)
Fibrin D dimer increased (serious, 1 patient)
Haematocrit decreased (serious, 1 patient)
Haemoglobin decreased (serious, 6 patients)
Heart rate irregular (serious, 1 patient)
Influenza virus test positive (serious, 1 patient)
International normalised ratio decreased (serious, 1 patient)
International normalised ratio fluctuation (serious, 1 patient)
International normalised ratio increased (serious, 2 patients)
Liver function test abnormal (serious, 1 patient)
Acidosis (serious, 3 patients)
Cachexia (serious, 4 patients)
Decreased appetite (serious, 3 patients)
Dehydration (serious, 6 patients)
Diabetic ketoacidosis (serious, 4 patients)
Failure to thrive (serious, 6 patients)
Hypercalcaemia (serious, 3 patients)
Hyperkalaemia (serious, 97 patients)
Hyperphosphataemia (serious, 1 patient)
Hypocalcaemia (serious, 16 patients)
Hypoglycaemia (serious, 34 patients)
Hyponatraemia (serious, 1 patient)
Lactic acidosis (serious, 1 patient)
Malnutrition (serious, 2 patients)
Hypoglycaemic shock (serious, 1 patient)
Type 1 diabetes mellitus (serious, 1 patient)
Arthralgia (serious, 11 patient)
Cervical spinal stenosis (serious, 2 patients)
Chondrocalcinosis pyrophosphate (serious, 1 patient)
Costochondritis (serious, 2 patients)
Intervertebral disc degeneration (serious, 1 patient)
Intervertebral disc disorder (serious, 2 patients)
Intervertebral disc protrusion (serious, 6 patients)
Destruction joint (serious, 1 patient)
Limb deformity (serious, 1 patient)
Mobility decreased (serious, 1 patient)
Muscular weakness (serious, 9 patients)
Musculoskeletal disorder (serious, 1 patient)
Musculoskeletal stiffness (serious, 1 patient)
Neuropathic arthropathy (serious, 1 patient)
Osteonecrosis (serious, 4 patients)
Osteopenia (serious, 1 patient)
Pain in extremity (serious, 13 patients)
Periarthritis (serious, 1 patient)
Pseudarthrosis (serious, 1 patient)
Arthropathy psoriatic (serious, 1 patient)
Rotator cuff syndrome (serious, 2 patients)
Scleroderma (serious, 1 patient)
Spinal column stenosis (serious, 1 patient)
Spondylolisthesis (serious, 1 patient)
Acute myeloid leukaemia (serious, 1 patient)
Adenocarcinoma (serious, 1 patient)
Adenoma benign (serious, 1 patient)
B-cell lymphoma (serious, 1 patient)
Bladder cancer (serious, 4 patients)
Bladder cancer recurrent (serious, 1 patient)
Bladder neoplasm (serious, 3 patients)
Brain cancer metastatic (serious, 1 patient)
Brain neoplasm (serious, 1 patient)
Breast cancer (serious, 7 patients)
Breast cancer metastatic (serious, 2 patients)
Chronic lymphocytic leukaemia (serious, 1 patient)
Chronic myeloid leukaemia (serious, 1 patient)
Colon neoplasm (serious, 1 patient)
Hepatic neoplasm malignant (serious, 1 patient)
Intraocular melanoma (serious, 1 patient)
Lentigo maligna stage unspecified (serious, 1 patient)
Adenocarcinoma lung (serious, 2 patients)
Lung neoplasm malignant (serious, 4 patients)
Lymphoma (serious, 1 patient)
Malignant melanoma (serious, 2 patients)
Malignant pleural effusion (serious, 1 patient)
Malignant urinary tract neoplasm (serious, 1 patient)
Metastases to central nervous system (serious, 1 patient)
Metastases to lung (serious, 1 patient)
Metastases to peritoneum (serious, 1 patient)
Metastatic malignant melanoma (serious, 1 patient)
Metastatic neoplasm (serious, 4 patients)
Neoplasm malignant (serious, 1 patient)
Neoplasm skin (serious, 2 patients)
Non-Hodgkin's lymphoma (serious, 1 patient)
Pancreatic carcinoma (serious, 2 patients)
Prostate cancer (serious, 8 patients)
Prostate cancer metastatic (serious, 1 patient)
Renal cell carcinoma (serious, 6 patients)
Renal oncocytoma (serious, 1 patient)
Small cell lung cancer stage unspecified (serious, 1 patient)
Neoplasm thyroid (serious, 3 patients)
Transitional cell carcinoma (serious, 1 patient)
Tumour haemorrhage (serious, 1 patient)
Vaginal cancer (serious, 1 patient)
Aphasia (serious, 1 patient)
Autonomic neuropathy (serious, 2 patients)
Balance disorder (serious, 3 patients)
Basal ganglia haemorrhage (serious, 1 patient)
Brain stem infarction (serious, 1 patient)
Cerebral atrophy (serious, 1 patient)
Cerebral haemorrhage (serious, 10 patients)
Cerebral infarction (serious, 5 patients)
Clonus (serious, 1 patient)
Coma (serious, 3 patients)
Convulsion (serious, 30 patients)
Dizziness (serious, 9 patients)
Dyskinesia (serious, 1 patient)
Encephalitis (serious, 1 patient)
Encephalitis post varicella (serious, 1 patient)
Encephalomalacia (serious, 1 patient)
Epilepsy (serious, 3 patients)
Extrapyramidal disorder (serious, 2 patients)
Guillain Barre syndrome (serious, 1 patient)
Haemorrhage intracranial (serious, 7 patients)
Headache (serious, 6 patients)
Hemianopia (serious, 1 patient)
Hypogeusia (serious, 1 patient)
Hypoglycaemic encephalopathy (serious, 1 patient)
Hypotonia (serious, 1 patient)
Hypoxic-ischaemic encephalopathy (serious, 4 patients)
Ischaemic stroke (serious, 8 patients)
Migraine (serious, 2 patients)
Myelitis transverse (serious, 1 patient)
Nerve compression (serious, 2 patients)
Neuralgia (serious, 1 patient)
Optic neuritis (serious, 1 patient)
Paraesthesia (serious, 2 patients)
Partial seizures (serious, 1 patient)
Post herpetic neuralgia (serious, 1 patient)
Presyncope (serious, 3 patients)
Somnolence (serious, 2 patients)
Status epilepticus (serious, 3 patients)
Stupor (serious, 1 patient)
Haemorrhage subarachnoid (serious, 5 patients)
Transient ischaemic attack (serious, 15 patients)
Tremor (serious, 2 patients)
Uraemic encephalopathy (serious, 2 patients)
Uraemic neuropathy (serious, 1 patient)
Dementia vascular (serious, 2 patients)
Bipolar disorder (serious, 1 patient)
Confusional state (serious, 8 patients)
Conversion disorder (serious, 1 patient)
Disorientation (serious, 2 patients)
Drug abuse (serious, 2 patients)
Hallucination (serious, 1 patient)
Major depression (serious, 2 patients)
Psychotic disorder (serious, 2 patients)
Restlessness (serious, 1 patient)
Schizophrenia (serious, 1 patient)
Substance abuse (serious, 1 patient)
Suicidal ideation (serious, 2 patients)
Calculus ureteric (serious, 1 patient)
Cystitis haemorrhagic (serious, 2 patients)
Nephrolithiasis (serious, 2 patients)
Colic renal (serious, 2 patients)
Renal cyst haemorrhage (serious, 1 patient)
Renal haemorrhage (serious, 4 patients)
Renal injury (serious, 1 patient)
Renal tubular necrosis (serious, 2 patients)
Urethral prolapse (serious, 1 patient)
Urethral stenosis (serious, 2 patients)
Haemorrhage urinary bladder (serious, 1 patient)
Breast inflammation (serious, 1 patient)
Epididymitis (serious, 1 patient)
Female genital tract fistula (serious, 1 patient)
Disease fibrocystic breast (serious, 1 patient)
Menometrorrhagia (serious, 1 patient)
Menorrhagia (serious, 1 patient)
Pelvic adhesions (serious, 1 patient)
Priapism (serious, 1 patient)
Scrotal haematocoele (serious, 1 patient)
Scrotal pain (serious, 1 patient)
Scrotal swelling (serious, 1 patient)
Testicular haemorrhage (serious, 1 patient)
Uterine polyp (serious, 2 patients)
Vaginal laceration (serious, 1 patient)
Prolapse vaginal (serious, 1 patient)
Atelectasis (serious, 4 patients)
Chronic obstructive pulmonary disease (serious, 20 patients)
Dyspnoea (serious, 47 patients)
Dyspnoea exertional (serious, 1 patient)
Epistaxis (serious, 10 patients)
Haemothorax (serious, 3 patients)
Hypercapnia (serious, 2 patients)
Hypoventilation (serious, 1 patient)
Interstitial lung disease (serious, 3 patients)
Laryngeal cyst (serious, 1 patient)
Lung consolidation (serious, 2 patients)
Lung infiltration (serious, 2 patients)
Nasal septum deviation (serious, 1 patient)
Pleural disorder (serious, 1 patient)
Pleural effusion (serious, 32 patients)
Aspiration pneumonia (serious, 4 patients)
Pneumonitis (serious, 5 patients)
Pulmonary alveolar haemorrhage (serious, 1 patient)
Pulmonary arterial hypertension (serious, 1 patient)
Pulmonary fibrosis (serious, 1 patient)
Pulmonary necrosis (serious, 1 patient)
Respiratory arrest (serious, 8 patients)
Respiratory disorder (serious, 1 patient)
Respiratory distress (serious, 5 patients)
Status asthmaticus (serious, 1 patient)
Stridor (serious, 1 patient)
Tachypnoea (serious, 1 patient)
Vocal cord polyp (serious, 1 patient)
Angioedema (serious, 3 patients)
Dermal cyst (serious, 2 patients)
Dermatitis acneiform (serious, 1 patient)
Diabetic foot (serious, 9 patients)
Erythema nodosum (serious, 1 patient)
Abnormal hair growth (serious, 1 patient)
Hidradenitis (serious, 1 patient)
Hyperkeratosis (serious, 1 patient)
Necrosis skin (serious, 4 patients)
Subcutaneous emphysema (serious, 1 patient)
Activities of daily living impaired (serious, 1 patient)
Treatment noncompliance (serious, 1 patient)
Incisional drainage (serious, 1 patient)
Therapy cessation (serious, 5 patients)
Aneurysm (serious, 1 patient)
Angiopathy (serious, 1 patient)
Aortic aneurysm rupture (serious, 2 patients)
Arterial haemorrhage (serious, 1 patient)
Arterial insufficiency (serious, 1 patient)
Arterial stenosis (serious, 3 patients)
Arteritis (serious, 5 patients)
Deep vein thrombosis (serious, 10 patients)
Diabetic macroangiopathy (serious, 1 patient)
Diabetic vascular disorder (serious, 3 patients)
Femoral arterial stenosis (serious, 8 patients)
Femoral artery occlusion (serious, 1 patient)
Haemorrhage (serious, 5 patients)
Hypertension (serious, 49 patients)
Hypertensive crisis (serious, 29 patients)
Hypertensive emergency (serious, 12 patients)
Hypotension (serious, 54 patients)
Iliac artery occlusion (serious, 1 patient)
Iliac artery stenosis (serious, 4 patients)
Intra-abdominal haematoma (serious, 2 patients)
Ischaemic limb pain (serious, 2 patients)
Hypertension malignant (serious, 6 patients)
Orthostatic hypotension (serious, 5 patients)
Peripheral arterial occlusive disease (serious, 13 patients)
Peripheral artery aneurysm (serious, 1 patient)
Disorder peripheral vascular (serious, 30 patients)
Phlebitis (serious, 2 patients)
Steal syndrome (serious, 7 patients)
Subclavian artery aneurysm (serious, 1 patient)
Subclavian artery stenosis (serious, 1 patient)
Superior vena cava syndrome (serious, 7 patients)
Systolic hypertension (serious, 1 patient)
Superficial thrombophlebitis (serious, 1 patient)
Thrombosis (serious, 4 patients)
Varicose ulceration (serious, 2 patients)
Vascular calcification (serious, 2 patients)
Vascular occlusion (serious, 1 patient)
Vena cava thrombosis (serious, 1 patient)
Venous aneurysm (serious, 1 patient)
Venous occlusion (serious, 4 patients)
Venous stenosis (serious, 9 patients)
Anaemia (below serious, 109 patients)
Abdominal pain (below serious, 187 patients)
Abdominal pain upper (below serious, 153 patients)
Diarrhoea (below serious, 376 patients)
Dyspepsia (below serious, 140 patients)
Nausea (below serious, 552 patients)
Vomiting (below serious, 482 patients)
Chest pain (below serious, 134 patients)
Oedema peripheral (below serious, 117 patients)
Bronchitis (below serious, 138 patients)
Nasopharyngitis (below serious, 157 patients)
Upper respiratory tract infection (below serious, 144 patients)
Urinary tract infection (below serious, 114 patients)
Arteriovenous fistula site complication (below serious, 124 patients)
Decreased appetite (below serious, 112 patients)
Hypocalcaemia (below serious, 206 patients)
Back pain (below serious, 159 patients)
Muscle spasms (below serious, 213 patients)
Pain in extremity (below serious, 201 patient)
Dizziness (below serious, 135 patients)
Headache (below serious, 219 patients)
Cough (below serious, 225 patients)
Dyspnoea (below serious, 226 patients)
Hypertension (below serious, 176 patients)
Hypotension (below serious, 183 patients)
Sources:
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Other AEs: Anaemia, Glaucoma...
Other AEs:
Anaemia (serious, 1 patient)
Glaucoma (serious, 1 patient)
Abdominal hernia (serious, 1 patient)
Abdominal pain upper (serious, 1 patient)
Diarrhoea (serious, 1 patient)
Hernia inguinal (serious, 1 patient)
Pancreatitis acute (serious, 1 patient)
Influenza like illness (serious, 1 patient)
Kidney transplant rejection (serious, 1 patient)
Cystitis (serious, 1 patient)
Cytomegalovirus infection (serious, 2 patients)
Gastroenteritis viral (serious, 1 patient)
Lung infection (serious, 1 patient)
Pneumonia (serious, 1 patient)
Foot fracture (serious, 1 patient)
Lung adenocarcinoma metastatic (serious, 1 patient)
Cerebrovascular accident (serious, 1 patient)
Renal impairment (serious, 1 patient)
Lung infiltration (serious, 1 patient)
Abdominal discomfort (below serious, 3 patients)
Diarrhoea (below serious, 8 patients)
Nausea (below serious, 7 patients)
Malaise (below serious, 4 patients)
Upper respiratory tract infection (below serious, 5 patients)
Urinary tract infection (below serious, 8 patients)
Gout (below serious, 3 patients)
Hypercholesterolaemia (below serious, 4 patients)
Hyperlipidaemia (below serious, 3 patients)
Hypokalaemia (below serious, 4 patients)
Hypomagnesaemia (below serious, 5 patients)
Arthralgia (below serious, 3 patients)
Back pain (below serious, 5 patients)
Headache (below serious, 5 patients)
Insomnia (below serious, 3 patients)
Cough (below serious, 8 patients)
Oropharyngeal pain (below serious, 3 patients)
Hypertension (below serious, 5 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Diarrhea 1 patient
100 mg single, oral
Highest studied dose
Dose: 100 mg
Route: oral
Route: single
Dose: 100 mg
Sources:
healthy, 20 - 35 years
n = 6
Health Status: healthy
Age Group: 20 - 35 years
Sex: M
Population Size: 6
Sources:
Nasal congestion 1 patient
100 mg single, oral
Highest studied dose
Dose: 100 mg
Route: oral
Route: single
Dose: 100 mg
Sources:
healthy, 20 - 35 years
n = 6
Health Status: healthy
Age Group: 20 - 35 years
Sex: M
Population Size: 6
Sources:
Peripheral sensory neuropathy 1 patient
100 mg single, oral
Highest studied dose
Dose: 100 mg
Route: oral
Route: single
Dose: 100 mg
Sources:
healthy, 20 - 35 years
n = 6
Health Status: healthy
Age Group: 20 - 35 years
Sex: M
Population Size: 6
Sources:
Vomiting 1 patient
100 mg single, oral
Highest studied dose
Dose: 100 mg
Route: oral
Route: single
Dose: 100 mg
Sources:
healthy, 20 - 35 years
n = 6
Health Status: healthy
Age Group: 20 - 35 years
Sex: M
Population Size: 6
Sources:
Dyspepsia 3 patients
100 mg single, oral
Highest studied dose
Dose: 100 mg
Route: oral
Route: single
Dose: 100 mg
Sources:
healthy, 20 - 35 years
n = 6
Health Status: healthy
Age Group: 20 - 35 years
Sex: M
Population Size: 6
Sources:
Anaemia below serious, 109 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Decreased appetite below serious, 112 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Urinary tract infection below serious, 114 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Oedema peripheral below serious, 117 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Arteriovenous fistula site complication below serious, 124 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Chest pain below serious, 134 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Dizziness below serious, 135 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Bronchitis below serious, 138 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Dyspepsia below serious, 140 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Upper respiratory tract infection below serious, 144 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Abdominal pain upper below serious, 153 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Nasopharyngitis below serious, 157 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Back pain below serious, 159 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hypertension below serious, 176 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hypotension below serious, 183 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Abdominal pain below serious, 187 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pain in extremity below serious, 201 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hypocalcaemia below serious, 206 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Muscle spasms below serious, 213 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Headache below serious, 219 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Cough below serious, 225 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Dyspnoea below serious, 226 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Diarrhoea below serious, 376 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Vomiting below serious, 482 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Nausea below serious, 552 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Abdominal distension serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Abdominal hernia obstructive serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Abdominal rigidity serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Abnormal hair growth serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Abscess neck serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Abscess of eyelid serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Abscess oral serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Abscess peritonsillar serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Achalasia oesophageal serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Activities of daily living impaired serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Acute myeloid leukaemia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Acute sinusitis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Adenocarcinoma serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Adenoma benign serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Adenomatous polyposis coli serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Adrenal insufficiency serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Age-related macular degeneration serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Amyloidosis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Anaemia haemolytic serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Aneurysm serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Angiopathy serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Animal bite serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Aphasia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Appendicitis perforated serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Arterial haemorrhage serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Arterial insufficiency serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Arteriosclerotic gangrene serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Arthropathy psoriatic serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Atrial tachycardia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Atrophy optic serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
B-cell lymphoma serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Bacterial infection serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Bacterial meningitis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Barrett's oesophagus serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Basal ganglia haemorrhage serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Biliary tract infection serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Bipolar disorder serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Bladder cancer recurrent serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Block bundle branch serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Blood calcium decreased serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Brain cancer metastatic serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Brain herniation serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Brain neoplasm serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Brain stem infarction serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Breast inflammation serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Calculus ureteric serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Cardioactive drug level increased serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Cardiovascular disorder serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Cataract cortical serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Catheter site pain serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Catheter site swelling serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Cellulitis orbital serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Cerebral atrophy serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Cholangitis acute serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Cholecystitis chronic serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Chondrocalcinosis pyrophosphate serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Chronic lymphocytic leukaemia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Chronic myeloid leukaemia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Clonus serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Clostridium colitis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Clostridium test positive serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Colon neoplasm serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Conversion disorder serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Coronary artery insufficiency serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Cryptococcal meningitis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Cystitis radiation serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Dermatitis acneiform serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Destruction joint serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Diabetic macroangiopathy serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Diabetic retinopathy serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Dieulafoy's vascular malformation serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Dilatation ventricular serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Disease fibrocystic breast serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Disorder vestibular serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Diverticulum serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Drug intolerance serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Drug withdrawal syndrome serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Dyskinesia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Dyspnoea exertional serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Electrocardiogram ST segment abnormal serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Electrocardiogram ST-T segment abnormal serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Encephalitis post varicella serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Encephalitis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Encephalomalacia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Enterobacter pneumonia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Enterococcal infection serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Epididymitis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Erosive oesophagitis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Erythema nodosum serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Escherichia bacteraemia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Exophthalmos serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Eye operation complication serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Face injury serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Fat necrosis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Female genital tract fistula serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Femoral artery occlusion serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Fibrin D dimer increased serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Foreign body serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Fractured coccyx serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Fungal oesophagitis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Gas gangrene serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Gastric hypermotility serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Gastritis haemorrhagic serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Gastroduodenitis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Gastrointestinal ulcer haemorrhage serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Giardiasis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Graft complication serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Graft haemorrhage serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Guillain Barre syndrome serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Haematocrit decreased serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Haemorrhage retroperitoneal serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Haemorrhage urinary bladder serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Haemorrhagic disorder serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Haemorrhagic erosive gastritis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hallucination serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Heart rate irregular serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Helicobacter infection serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hemianopia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hepatic function abnormal serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hepatic lesion serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hepatic neoplasm malignant serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hernia pain serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hernia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hernial eventration serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hidradenitis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hyperkeratosis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hyperphosphataemia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hypertensive retinopathy serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hypogeusia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hypoglycaemic encephalopathy serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hypoglycaemic shock serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hyponatraemia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hypotonia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hypoventilation serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Iliac artery occlusion serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Implant site haematoma serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Implant site infection serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Incisional drainage serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Infectious peritonitis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Infective aneurysm serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Infective tenosynovitis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Influenza like illness serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Influenza virus test positive serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
International normalised ratio decreased serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
International normalised ratio fluctuation serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Intervertebral disc degeneration serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Intestinal large ulcer serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Intestinal mass serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Intestinal perforation serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Intestinal ulcer serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Intraocular melanoma serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Irritable bowel syndrome serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Ischaemic gastritis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Joint abscess serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Kidney rupture serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Klebsiella bacteraemia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Lactic acidosis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Laryngeal cyst serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Left ventricle outflow tract obstruction serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Lentigo maligna stage unspecified serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Limb deformity serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Liver function test abnormal serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Localised oedema serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Lower respiratory tract infection bacterial serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Lumbar hernia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Lymphoma serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Malignant pleural effusion serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Malignant urinary tract neoplasm serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Mechanical ileus serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Meniere's disease serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Meningitis viral serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Menometrorrhagia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Menorrhagia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Metastases to central nervous system serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Metastases to lung serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Metastases to peritoneum serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Metastatic malignant melanoma serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Mitral valve calcification serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Mobility decreased serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Musculoskeletal disorder serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Musculoskeletal stiffness serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Myelitis transverse serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Nasal abscess serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Nasal septum deviation serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Necrosis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Necrotising colitis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Neoplasm malignant serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Neuralgia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Neuropathic arthropathy serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Non-Hodgkin's lymphoma serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Oesophageal food impaction serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Oesophageal perforation serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Oesophagitis haemorrhagic serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Optic neuritis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Orchitis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Organ failure serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Osteopenia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Partial seizures serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pelvic adhesions serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pelvic mass serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Peptic ulcer haemorrhage serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Periarthritis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Periorbital cellulitis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Peripheral artery aneurysm serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Peritoneal abscess serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pilonidal cyst serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pleural disorder serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pneumonia escherichia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pneumonia fungal serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pneumothorax traumatic serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Post herpetic neuralgia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Post procedural infection serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Post procedural pneumonia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Postoperative adhesion serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Postoperative ileus serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Postoperative thoracic procedure complication serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Precancerous mucosal lesion serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Priapism serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Procedural complication serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Prolapse vaginal serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Prostate cancer metastatic serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pseudarthrosis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pseudomonas infection serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pulmonary alveolar haemorrhage serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pulmonary arterial hypertension serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pulmonary fibrosis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pulmonary necrosis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pulmonary tuberculosis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pyelocystitis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Rectal abscess serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Renal cyst haemorrhage serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Renal injury serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Renal oncocytoma serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Respiratory disorder serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Respiratory tract infection bacterial serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Respiratory tract infection viral serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Restlessness serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Retinal vein thrombosis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Schizophrenia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Scleroderma serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Scrotal abscess serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Scrotal haematocoele serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Scrotal pain serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Scrotal swelling serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Serratia bacteraemia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Short-bowel syndrome serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Shunt aneurysm serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Small cell lung cancer stage unspecified serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Spinal column injury serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Spinal column stenosis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Splenic rupture serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Spondylolisthesis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Status asthmaticus serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Stomach mass serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Streptococcal sepsis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Stress ulcer serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Stridor serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Stupor serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Subclavian artery aneurysm serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Subclavian artery stenosis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Subcutaneous emphysema serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Subileus serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Substance abuse serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Superficial thrombophlebitis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Supraventricular extrasystoles serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Suture rupture serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Systemic inflammatory response syndrome serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Systolic hypertension serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Tachypnoea serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Testicular abscess serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Testicular haemorrhage serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Thyroid cyst serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Thyroiditis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Tooth abscess serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Tooth infection serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Tooth loss serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Tooth socket haemorrhage serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Transitional cell carcinoma serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Treatment noncompliance serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Tumour haemorrhage serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Type 1 diabetes mellitus serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Uraemic neuropathy serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Urethral prolapse serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Vaginal cancer serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Vaginal laceration serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Vascular occlusion serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Vena cava thrombosis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Venous aneurysm serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Ventricular tachyarrhythmia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Vertigo positional serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Vestibular neuronitis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Viral pharyngitis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Visual impairment serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Vocal cord polyp serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Wound infection bacterial serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Zygomycosis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Cerebral haemorrhage serious, 10 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Deep vein thrombosis serious, 10 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Epistaxis serious, 10 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Procedural hypotension serious, 10 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Shunt occlusion serious, 10 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Myocardial infarction serious, 109 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Arthralgia serious, 11 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Lower respiratory tract infection serious, 11 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Myocardial ischaemia serious, 11 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Upper gastrointestinal haemorrhage serious, 11 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Atrial flutter serious, 12 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Bradycardia serious, 12 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Cardiogenic shock serious, 12 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Gastric ulcer serious, 12 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hypertensive emergency serious, 12 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Staphylococcal sepsis serious, 12 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Ventricular tachycardia serious, 12 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Sepsis serious, 123 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Arteriovenous fistula occlusion serious, 13 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Endocarditis serious, 13 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pain in extremity serious, 13 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Peripheral arterial occlusive disease serious, 13 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Vascular graft complication serious, 13 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Infection staphylococcal serious, 14 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Transient ischaemic attack serious, 15 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Vascular access complication serious, 15 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Cholelithiasis serious, 16 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hypocalcaemia serious, 16 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Abdominal abscess serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Abdominal strangulated hernia serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Acetabulum fracture serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Adenocarcinoma lung serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Aortic aneurysm rupture serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Arteriovenous graft aneurysm serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Arthritis infective serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Autonomic neuropathy serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Blood pressure increased serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Breast cancer metastatic serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
C-reactive protein increased serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Catheter site cellulitis serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Cervical spinal stenosis serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Cholestasis serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Chronic pancreatitis serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Coagulopathy serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Colic renal serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Conjunctivitis serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Costochondritis serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Cystitis haemorrhagic serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Dementia vascular serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Dengue fever serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Dermal cyst serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Device dislocation serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Device occlusion serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Diabetic gastroparesis serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Disorientation serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Diverticular perforation serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Drug abuse serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Electrocardiogram abnormal serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Enteritis infectious serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Enterobacter bacteraemia serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Enterocolitis infectious serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Extrapyramidal disorder serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Eye infection serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Gallbladder polyp serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Gastric ulcer haemorrhage serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Gastrointestinal angiodysplasia serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Gastrointestinal arteriovenous malformation serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Gastrointestinal inflammation serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Haematoma infection serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Haemophilus infection serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hepatitis C serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hiatus hernia serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hypercapnia serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hyperthermia serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
In-stent coronary artery restenosis serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
International normalised ratio increased serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Intervertebral disc disorder serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Intestinal haemorrhage serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Intra-abdominal haematoma serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Ischaemic limb pain serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Left ventricular dysfunction serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Leukopenia serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Lung consolidation serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Lung infiltration serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Major depression serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Malignant melanoma serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Malnutrition serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Mesenteric artery stenosis serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Migraine serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Mitral valve disease serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Neoplasm skin serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Nephrolithiasis serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Nerve compression serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Neutropenia serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pancreatic carcinoma serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Paraesthesia serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Parathyroid gland enlargement serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Perirectal abscess serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Phlebitis serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pneumonia primary atypical serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pneumonia viral serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Postoperative wound complication serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Psychotic disorder serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pyelonephritis acute serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Renal cyst infection serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Renal tubular necrosis serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Right ventricular failure serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Rotator cuff syndrome serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Sinus tachycardia serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Somnolence serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Spinal pain serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Staphylococcal osteomyelitis serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Suicidal ideation serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Tremor serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Uraemic encephalopathy serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Urethral stenosis serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Uterine polyp serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Varicose ulceration serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Vascular calcification serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Vitreous haemorrhage serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Wound infection staphylococcal serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Chronic obstructive pulmonary disease serious, 20 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Nausea serious, 20 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Gastroenteritis serious, 24 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Arteriovenous graft site infection serious, 25 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Bronchitis serious, 26 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Bacteraemia serious, 27 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Cardio-respiratory arrest serious, 27 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Non-cardiac chest pain serious, 27 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Coronary artery disease serious, 28 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Device related infection serious, 29 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hypertensive crisis serious, 29 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Abscess serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Acidosis serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Angioedema serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Arterial stenosis serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Arteriovenous fistula site haematoma serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Balance disorder serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Bile duct stone serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Bladder neoplasm serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Catheter site haematoma serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Cholangitis serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Clostridial infection serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Coma serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Complications of transplanted kidney serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Decreased appetite serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Diabetic vascular disorder serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Dyspepsia serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Dysphagia serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Electrocardiogram change serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Enterobacter sepsis serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Enterococcal bacteraemia serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Epilepsy serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Eye haemorrhage serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Faecaloma serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Forearm fracture serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Fracture serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
H1N1 influenza serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Haemothorax serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hypercalcaemia serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Infected fistula serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Interstitial lung disease serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Melaena serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Neoplasm thyroid serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pelvic fracture serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pericarditis serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Postoperative abscess serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Presyncope serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Retinal detachment serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Status epilepticus serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Transplant failure serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Convulsion serious, 30 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Disorder peripheral vascular serious, 30 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Diarrhoea serious, 32 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pleural effusion serious, 32 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Vomiting serious, 33 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hypoglycaemia serious, 34 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Abdominal wall abscess serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Arthritis bacterial serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Aspiration pneumonia serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Atelectasis serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Bladder cancer serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Blood potassium increased serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Cachexia serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Chest discomfort serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Chills serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Contusion serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Diabetic ketoacidosis serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Gastrooesophageal reflux disease serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Haemodialysis-induced symptom serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Herpes zoster serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hypoxic-ischaemic encephalopathy serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Iliac artery stenosis serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Influenza serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Leukocytosis serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Lung neoplasm malignant serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Metastatic neoplasm serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Necrosis skin serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Osteonecrosis serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Renal haemorrhage serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Thrombosis serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Venous occlusion serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Vertigo serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Wound dehiscence serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Anaemia serious, 42 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pyrexia serious, 42 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Acute myocardial infarction serious, 47 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Dyspnoea serious, 47 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Arteriovenous fistula thrombosis serious, 49 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hypertension serious, 49 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Abdominal pain upper serious, 5 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Arteritis serious, 5 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Atrioventricular block serious, 5 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Cerebral infarction serious, 5 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Coronary artery stenosis serious, 5 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Enteritis serious, 5 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Haematemesis serious, 5 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Haemorrhage subarachnoid serious, 5 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Haemorrhage serious, 5 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Haemorrhagic anaemia serious, 5 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Haemorrhoids serious, 5 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Intestinal obstruction serious, 5 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Joint dislocation serious, 5 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Orthostatic hypotension serious, 5 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pneumonitis serious, 5 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Post procedural haemorrhage serious, 5 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Respiratory distress serious, 5 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Small intestinal obstruction serious, 5 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Therapy cessation serious, 5 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Viral infection serious, 5 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Angina unstable serious, 52 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Gastrointestinal haemorrhage serious, 54 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hypotension serious, 54 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Appendicitis serious, 6 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Cardiac failure acute serious, 6 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Congenital cystic kidney disease serious, 6 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Dehydration serious, 6 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Failure to thrive serious, 6 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Haemoglobin decreased serious, 6 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Headache serious, 6 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hypertension malignant serious, 6 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Ileus serious, 6 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Impaired gastric emptying serious, 6 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Intervertebral disc protrusion serious, 6 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Kidney transplant rejection serious, 6 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Oesophagitis serious, 6 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Overdose serious, 6 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Palpitations serious, 6 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Renal cell carcinoma serious, 6 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Shunt stenosis serious, 6 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Subcutaneous abscess serious, 6 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Cardiac arrest serious, 60 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Aortic valve stenosis serious, 7 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Breast cancer serious, 7 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Cholecystitis acute serious, 7 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Duodenal ulcer serious, 7 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Graft thrombosis serious, 7 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Haemorrhage intracranial serious, 7 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Steal syndrome serious, 7 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Superior vena cava syndrome serious, 7 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Upper respiratory tract infection serious, 7 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Cataract serious, 8 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Confusional state serious, 8 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Constipation serious, 8 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Femoral arterial stenosis serious, 8 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Gastroenteritis viral serious, 8 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Ischaemic stroke serious, 8 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Multi-organ failure serious, 8 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pericardial effusion serious, 8 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Prostate cancer serious, 8 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Respiratory arrest serious, 8 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Shunt thrombosis serious, 8 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Subdural haematoma serious, 8 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Vascular graft occlusion serious, 8 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Vascular pseudoaneurysm serious, 8 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Abscess limb serious, 9 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Ankle fracture serious, 9 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Arteriovenous graft site haemorrhage serious, 9 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Clostridium difficile colitis serious, 9 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Colitis ischaemic serious, 9 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Diabetic foot serious, 9 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Diverticulitis serious, 9 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Dizziness serious, 9 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Intestinal ischaemia serious, 9 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Muscular weakness serious, 9 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Peritonitis serious, 9 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Pyelonephritis serious, 9 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Staphylococcal bacteraemia serious, 9 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Venous stenosis serious, 9 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Hyperkalaemia serious, 97 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 1938
Health Status: unhealthy
Condition: Secondary Hyperparathyroidism
Population Size: 1938
Sources:
Abdominal discomfort below serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Arthralgia below serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Gout below serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Hyperlipidaemia below serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Insomnia below serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Oropharyngeal pain below serious, 3 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Hypercholesterolaemia below serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Hypokalaemia below serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Malaise below serious, 4 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Back pain below serious, 5 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Headache below serious, 5 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Hypertension below serious, 5 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Hypomagnesaemia below serious, 5 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Upper respiratory tract infection below serious, 5 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Nausea below serious, 7 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Cough below serious, 8 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Diarrhoea below serious, 8 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Urinary tract infection below serious, 8 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Abdominal hernia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Abdominal pain upper serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Anaemia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Cerebrovascular accident serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Cystitis serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Diarrhoea serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Foot fracture serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Gastroenteritis viral serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Glaucoma serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Hernia inguinal serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Influenza like illness serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Kidney transplant rejection serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Lung adenocarcinoma metastatic serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Lung infection serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Lung infiltration serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Pancreatitis acute serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Pneumonia serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Renal impairment serious, 1 patient
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Cytomegalovirus infection serious, 2 patients
180 mg 1 times / day steady, oral (max)
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Hyperparathyroidism
Population Size: 57
Sources:
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​Drug as victimTox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.
2002 Apr
Gateways to clinical trials.
2002 Nov
Cinacalcet: AMG 073, Calcimimetics--Amgen/NPS Pharmaceuticals, KRN 1493, NPS 1493.
2003
Cinacalcet: Amg 073, calcimimetics--Amgen/NPS Pharmaceuticals.
2003
Cinacalcet HCl: a calcimimetic agent for the management of primary and secondary hyperparathyroidism.
2003 Aug
The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
2003 Jan
Gateways to clinical trials.
2003 Sep
Fooling the parathyroid gland--will there be health benefits?
2004 Apr 8
Clinical experience with cinacalcet HCl.
2004 Aug
The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis.
2004 Jun
Calcimimetic and calcilytic drugs: just for parathyroid cells?
2004 Mar
[Clinical application of calcimimetics].
2004 May
First treatment for serious complications of kidney disease, parathyroid cancer.
2004 May-Jun
Calcimimetics and the treatment of primary and secondary hyperparathyroidism.
2004 Nov
New agents for the treatment of renal osteodystrophy.
2004 Oct-Dec
Gateways to clinical trials.
2004 Sep
Management of renal osteodystrophy in children.
2005
No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar/Mimpara).
2005
New prospects for the management of renal bone disease.
2005
Cinacalcet hydrochloride: a viewpoint by Sharon M. Moe.
2005
Calcium-sensing receptor gene polymorphism Arg990Gly and its possible effect on response to cinacalcet HCl.
2005 Jan
Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis.
2005 Jul
Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease.
2005 Jul
1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.
2005 Jul
Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease.
2005 Jun
Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism.
2005 Jun
Treatment of secondary hyperparathyroidism of dialysis patients with calcimimetics as a valuable addition to established therapeutic means.
2005 Mar
How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
2005 May-Jun
Cinacalcet and vascular calcifications induced by calcitriol.
2006 Feb
Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: correlation with posttranslational modification of the trans acting factor AUF1.
2006 Jan
Patents

Sample Use Guides

Secondary HPT in patients with CKD on dialysis: starting dose is 30 mg once daily. Hypercalcemia: starting dose is 30 mg twice daily.
Route of Administration: Oral
Cinacalcet (100 nM) suppressed parathyroid hormone secretion in human parathyroid cells.
Substance Class Chemical
Created
by admin
on Sat Jun 26 01:51:25 UTC 2021
Edited
by admin
on Sat Jun 26 01:51:25 UTC 2021
Record UNII
UAZ6V7728S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CINACALCET
EMA EPAR   HSDB   INN   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
CINACALCET [WHO-DD]
Common Name English
AMG-073
Code English
CINACALCET [HSDB]
Common Name English
1-NAPHTHALENEMETHANAMINE, .ALPHA.-METHYL-N-(3-(3-(TRIFLUOROMETHYL)PHENYL)PROPYL)-, (.ALPHA.R)-
Common Name English
CINACALCET [EMA EPAR]
Common Name English
KRN1493
Code English
CINACALCET [MI]
Common Name English
AMG073
Code English
CINACALCET [USAN]
Common Name English
N-((1R)-1-(NAPHTHALEN-1-YL)ETHYL)-3-(3-(TRIFLUOROMETHYL)PHENYL)PROPAN-1-AMINE
Systematic Name English
CINACALCET [VANDF]
Common Name English
AMG 073
Code English
KRN-1493
Code English
CINACALCET [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C2136
Created by admin on Sat Jun 26 01:51:25 UTC 2021 , Edited by admin on Sat Jun 26 01:51:25 UTC 2021
WHO-VATC QH05BX01
Created by admin on Sat Jun 26 01:51:25 UTC 2021 , Edited by admin on Sat Jun 26 01:51:25 UTC 2021
WHO-ATC H05BX01
Created by admin on Sat Jun 26 01:51:25 UTC 2021 , Edited by admin on Sat Jun 26 01:51:25 UTC 2021
NDF-RT N0000020081
Created by admin on Sat Jun 26 01:51:25 UTC 2021 , Edited by admin on Sat Jun 26 01:51:25 UTC 2021
NDF-RT N0000175902
Created by admin on Sat Jun 26 01:51:25 UTC 2021 , Edited by admin on Sat Jun 26 01:51:25 UTC 2021
FDA ORPHAN DRUG 163402
Created by admin on Sat Jun 26 01:51:25 UTC 2021 , Edited by admin on Sat Jun 26 01:51:25 UTC 2021
EMA ASSESSMENT REPORTS MIMPARA (AUTHORIZED: HYPERPARATHYROIDISM, PARATHYROID NEOPLASMS, HYPERCALCEMIA)
Created by admin on Sat Jun 26 01:51:25 UTC 2021 , Edited by admin on Sat Jun 26 01:51:25 UTC 2021
FDA ORPHAN DRUG 165102
Created by admin on Sat Jun 26 01:51:25 UTC 2021 , Edited by admin on Sat Jun 26 01:51:25 UTC 2021
FDA ORPHAN DRUG 511315
Created by admin on Sat Jun 26 01:51:25 UTC 2021 , Edited by admin on Sat Jun 26 01:51:25 UTC 2021
EMA ASSESSMENT REPORTS PARAREG (WITHDRAWN: HYPERPARATHYROIDISM, PARATHYROID NEOPLASMS, HYPERCALCEMIA)
Created by admin on Sat Jun 26 01:51:25 UTC 2021 , Edited by admin on Sat Jun 26 01:51:25 UTC 2021
Code System Code Type Description
INN
8287
Created by admin on Sat Jun 26 01:51:25 UTC 2021 , Edited by admin on Sat Jun 26 01:51:25 UTC 2021
PRIMARY
EPA CompTox
226256-56-0
Created by admin on Sat Jun 26 01:51:25 UTC 2021 , Edited by admin on Sat Jun 26 01:51:25 UTC 2021
PRIMARY
MESH
C476217
Created by admin on Sat Jun 26 01:51:25 UTC 2021 , Edited by admin on Sat Jun 26 01:51:25 UTC 2021
PRIMARY
PUBCHEM
156419
Created by admin on Sat Jun 26 01:51:25 UTC 2021 , Edited by admin on Sat Jun 26 01:51:25 UTC 2021
PRIMARY
WIKIPEDIA
Cinacalcet
Created by admin on Sat Jun 26 01:51:25 UTC 2021 , Edited by admin on Sat Jun 26 01:51:25 UTC 2021
PRIMARY
NCI_THESAURUS
C74100
Created by admin on Sat Jun 26 01:51:25 UTC 2021 , Edited by admin on Sat Jun 26 01:51:25 UTC 2021
PRIMARY
EVMPD
SUB25416
Created by admin on Sat Jun 26 01:51:25 UTC 2021 , Edited by admin on Sat Jun 26 01:51:25 UTC 2021
PRIMARY
HSDB
7318
Created by admin on Sat Jun 26 01:51:25 UTC 2021 , Edited by admin on Sat Jun 26 01:51:25 UTC 2021
PRIMARY
ChEMBL
CHEMBL1201284
Created by admin on Sat Jun 26 01:51:25 UTC 2021 , Edited by admin on Sat Jun 26 01:51:25 UTC 2021
PRIMARY
IUPHAR
3308
Created by admin on Sat Jun 26 01:51:25 UTC 2021 , Edited by admin on Sat Jun 26 01:51:25 UTC 2021
PRIMARY
RXCUI
407990
Created by admin on Sat Jun 26 01:51:25 UTC 2021 , Edited by admin on Sat Jun 26 01:51:25 UTC 2021
PRIMARY RxNorm
DRUG CENTRAL
647
Created by admin on Sat Jun 26 01:51:25 UTC 2021 , Edited by admin on Sat Jun 26 01:51:25 UTC 2021
PRIMARY
MERCK INDEX
M3555
Created by admin on Sat Jun 26 01:51:25 UTC 2021 , Edited by admin on Sat Jun 26 01:51:25 UTC 2021
PRIMARY Merck Index
FDA UNII
UAZ6V7728S
Created by admin on Sat Jun 26 01:51:25 UTC 2021 , Edited by admin on Sat Jun 26 01:51:25 UTC 2021
PRIMARY
CAS
226256-56-0
Created by admin on Sat Jun 26 01:51:25 UTC 2021 , Edited by admin on Sat Jun 26 01:51:25 UTC 2021
PRIMARY
DRUG BANK
DB01012
Created by admin on Sat Jun 26 01:51:25 UTC 2021 , Edited by admin on Sat Jun 26 01:51:25 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
MAJOR
TARGET -> AGONIST
METABOLIC ENZYME -> SUBSTRATE
MAJOR
METABOLIC ENZYME -> SUBSTRATE
MAJOR
BINDER->LIGAND
BINDING
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

Biological Half-life PHARMACOKINETIC